Erlotinib in the treatment of advanced pancreatic cancer

Figures & data

Figure 1 Kaplan-Meier curves for (A) overall survival; and (B) progression-free survival. HR = hazard ratio. Reproduced with permission from Moore MJ, Goldstein D, Hamm J, et al 2007b. Erlotinib plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960–6. Copyright © 2007. American Society of Clinical Oncology.

Figure 2 Overall survival by grade of rash in patients treated with erlotinib in PA.3 study. Reproduced with permission from Moore MJ, Goldstein D, Hamm J, et al 2007b. Erlotinib plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960–6. Copyright © 2007. American Society of Clinical Oncology.

Table 1 Clinical trials of erlotinib in advanced pancreatic cancer

Reference	Type of trial	No. of patients	Prior treatments	Regimen	Erlotinib dose/day	Activity
Porterfield 2005	Phase I	14	No prior G	G + E	100–150 mg	PR 7% MR 21% SD 42%
Moore 2007	Phase III	569	No prior chemo- therapya	Randomized G + E or G + P	100–150 mg	G + E arm: CR + PR 8.6% SD 48.9% OS 6.24 mo. PFS 3.75 mo.
Blaszkowsky 2005	Phase II	28	Failed G	CAPE + E	150 mg	PR 11% SD 57% MS 6.7 mo.
Kindler 2006	Phase II	58	No prior chemo- therapy	Randomized GBE or GBC	150 mg	GBE arm: PR 21% SD 67% PFS 3.6 mo.
Gomez-Martin 2007b	Phase I	12	NR	E + B + Gc	150 mg	Incomplete data
Epelbaum 2007	Phase I	13	Failed ≥ 1 prior chemotherapy	E	150 mg	CI 23% SD 15%
Ko 2007	Phase II	25	Failed 1–3 prior chemotherapies	E + B	150 mg	PR 4% SD 28%

a Except fluorouracil or gemcitabine as radiosensitizer.

b Phase I study ongoing.

c Gemcitabine doses 850 mg/m² or 1000 mg/m².

Abbreviations: G, gemcitabine; E, erlotinib; PR, partial response; MR, minor response; SD, stable disease; P, placebo; CR, complete response; PFS, progression free survival; CAPE, capecitabine; MS, median survival; GBE, gemcitabine, bevacizumab, and erlotinib; GBC, gemcitabine, bevacizumab, and cetuximab; NR, not reported; CI, clinical improvement.

MooreMJGoldsteinDHammJ2007bErlotinib plus gemictabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol251960617452677

 PubMed Web of Science ®Google Scholar

MooreMJda Cunha SantosGKamel-ReidS2007aThe relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3J Clin Oncol2518S abstract 4521

 Google Scholar

BlaszkowskyLSKulkeKHRyanKP2005A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancerJ Clin Oncol2316S abstract 4099

 PubMedGoogle Scholar

KindlerHLBylowKAHochsterHS2006A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysisJ Clin Oncol2418s abstract 4040

 Google Scholar

Gomez-MartinCCamaraJCCortesH2007A phase I study of erlotinib, bevacizumab, and gemcitabine in patients with advanced pancreatic cancerJ Clin Oncol2518s abstract 4611

 Google Scholar

EpelbaumRSchnaiderJGluzmanA2007Erlotinib as a single-agent therapy in patients with advanced pancreatic cancerASCO Gastrointestinal Cancers Symposium abstract 202

 Google Scholar

KoAHDitoESchillingerB2007A phase II trial of bevacizumab plus erlotinib for patients with metastatic gemcitabine-refractory pancreatic cancerASCO Gastrointestinal Cancers Symposium abstract 187

 Google Scholar